Alzamend Neuro, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALZN Nasdaq 2830 www.alzamend.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alzamend Neuro, Inc.

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule - Jun 16th, 2025 6:00 am
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - May 29th, 2025 6:00 am
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - May 19th, 2025 6:00 am
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - May 13th, 2025 6:00 am
EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants - May 13th, 2025 5:30 am
Alzamend Neuro Announces Reverse Stock Split - May 8th, 2025 6:00 am
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital - May 7th, 2025 6:00 am
EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program - May 7th, 2025 5:31 am
Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Apr 8th, 2025 7:55 am
Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? - Mar 28th, 2025 8:42 am
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital - Mar 25th, 2025 6:00 am
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital - Mar 18th, 2025 6:00 am
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital - Mar 11th, 2025 6:00 am
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital - Mar 4th, 2025 6:10 am
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital - Feb 25th, 2025 6:00 am
EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025 - Feb 25th, 2025 5:30 am
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital - Feb 19th, 2025 6:00 am
EXCLUSIVE: Alzamend Neuro Says Tesla Dynamic Completes Head Coil To Measure Brain Structure Lithium Levels - Feb 19th, 2025 5:30 am
Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year? - Jan 23rd, 2025 7:40 am
Alzamend Neuro to Present at the Sequire Investor Summit - Jan 15th, 2025 6:00 am